NR1I2 and Miyoshi myopathy: Above all, these data suggest that selectively targeting upstream regulators of the major PXR, FXR, LXR and Nrf2 pathways using a subset of synthetic antagonists or agonists for those xenobiotic receptors could provide a promising strategy to improve the efficacy of treatment in MM.